Nuclear factor-kappaB polypeptide inhibitor and application thereof

A peptide inhibitor and nuclear factor technology, applied in the field of medicine, can solve the problems of inability to improve the condition and the time should not be too long, and achieve the effect of preventing or treating rheumatoid arthritis

Inactive Publication Date: 2016-05-18
SUZHOU PULUODA BIOLOGICAL SCI & TECH
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

2. Steroid hormones. Hormones are very good analgesic and anti-inflammatory drugs, but long-term use alone cannot improve the condition, but bring many side effects. Steroids can be used as a transitional second-line slow-acting drug before it takes effect, but the dosage should be limited. small, not too long
However, there are no well-developed nuclear factor-κB peptide inhibitors available for the treatment of RA

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nuclear factor-kappaB polypeptide inhibitor and application thereof
  • Nuclear factor-kappaB polypeptide inhibitor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Immunoprotective Effects of Polypeptides in Collagen-Induced Mouse Arthritis Animal Model

[0014] A collagen-type mouse arthritis animal model was constructed to study the therapeutic effect of polypeptide on collagen-induced arthritis (CIA) in mice. Using mice as experimental animals, 90 SPF grade DBA / 1 mice (provided by Sino-British SIPPRLab.AnimalLtd), animal production license number: SCXK (Shanghai) 2008- 0016), male, 7-8 weeks old, with a body weight of 18-22g, were randomly divided into 9 groups, which were normal control group, model control group, 3 dosage groups of low, medium and high polypeptide (0.2, 0.4, 0.8mg / kg) and Positive drug control group (methotrexate 1mg / kg). Except the normal group, mice CIA models were established in each experimental group on the 0th day by dissolving chicken cartilage type II collagen (cII) with 0.1 mol / l acetic acid into a 4 mg / ml solution and overnight in a refrigerator at 4°C. On the day of the experiment, equal volumes ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of medicines and in particular relates to a polypeptide which contains an inhibition nuclear factor-kappaB and can be used for preventing and treating rheumatoid arthritis. A sequence of the polypeptide is KPARGDGFPAAM and is brand-new. The polypeptide provided by the invention has the beneficial effects that the polypeptide can be used for treating the rheumatoid arthritis and has potential new medicine development value.

Description

Technical field: [0001] The invention relates to the field of medicine, in particular to a nuclear factor-κB polypeptide inhibitor used for preventing and treating or preventing rheumatoid arthritis. Background technique: [0002] Rheumatoid arthritis (rheumatoid arthritis, RA) is the most common clinical inflammatory joint disease and one of the main disabling factors. It is about 0.5%-1.0% in the world, and the incidence of RA is about 0.4% in our country. RA can occur at any age, and the incidence rate increases with age. The high-incidence age of women is 45-55 years old, and gender is closely related to the incidence of RA, with a male-to-female ratio of about 1:3. RA is a chronic systemic inflammatory disease of unknown etiology, with chronic, symmetrical, polysynovial arthritis and extra-articular lesions as the main clinical manifestations, and belongs to autoimmune inflammatory disease. Patients often have hand or wrist pain and swelling (especially the swelling ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/08A61K38/10A61P19/02
CPCA61K38/00C07K7/08
Inventor 罗瑞雪
Owner SUZHOU PULUODA BIOLOGICAL SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products